ClinicalTrials.gg

Program

GC203

A development code. Also written as “GC203 TIL”, “GC203 TIL(gene-edited TIL) or autologous TILs” and “Engineering Tumor Infiltrating Lymphocytes”.

Its studies are mostly in Pancreatic Neoplasms · Breast Neoplasms, led by Shanghai Juncell Therapeutics.

Furthest: phase 1, since Apr 16, 20244 company-led studies, 4 open or runningNext primary completion: Nov 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Juncell Therapeutics44 open or runningphase 1since Apr 16, 2024Apr 16, 2024Nov 30, 2026phase 1 · NCT07256756

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 16, 2024First study: phase 1 study in Breast NeoplasmsFirst studyNCT06375187 · 18 planned · China
  2. Jun 27, 2024Early phase 1 study in Advanced Solid TumorNCT06488950 · 30 planned · China
  3. Feb 10, 2025Early phase 1 study in Pancreatic NeoplasmsNCT06828328 · 10 planned · China
  4. Nov 20, 2025Phase 1 study in Solid Tumors, AdultNCT07256756 · 8 planned · China

Ahead

  1. Nov 1, 2026Primary completion: phase 1 study in Breast NeoplasmsNCT06375187
  2. Nov 30, 2026Primary completion: phase 1 study in Solid Tumors, AdultNCT07256756
  3. Jan 31, 2028Primary completion: early phase 1 study in Pancreatic NeoplasmsNCT06828328

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07256756Solid Tumors, Adult · China1RecruitingNov 30, 20268
NCT06828328Pancreatic Neoplasms · ChinaEarly 1RecruitingJan 31, 202810
NCT06488950Advanced Solid Tumor · ChinaEarly 1RecruitingJun 30, 202630
NCT06375187Breast Neoplasms · China1RecruitingNov 1, 202618

How it is read

Names in the registry

  • “GC203 TIL”, 2 entries
  • “GC203 TIL(gene-edited TIL) or autologous TILs”, 1 entry
  • “Engineering Tumor Infiltrating Lymphocytes”, 1 entry

Codes read as this program: GC203.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.